Clifford A Hudis

List of Publications by Year
in descending order

446 papers	49,933 citations	1980 101 h-index	1745 212 g-index
458 all docs	458 docs citations	458 times ranked	43404 citing authors

#	Article	IF	Citations
1	CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2022, 40, 1323-1334.	0.8	62
2	The Breast Cancer Weight Loss trial (Alliance A011401): A description and evidence for the lifestyle intervention. Obesity, 2022, 30, 28-38.	1.5	9
3	Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy. Journal of the National Cancer Institute, 2021, 113, 443-452.	3.0	22
4	Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance). JNCI Cancer Spectrum, 2021, 5, pkab025.	1.4	8
5	Discrepancies in Financial Self-Disclosures and Open Payments Reporting Among Authors of Clinical Oncology Research Studies. Journal of Clinical Oncology, 2020, 38, 480-487.	0.8	3
6	Personalized Management of Chemotherapyâ€Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance). Journal of Clinical Pharmacology, 2020, 60, 444-452.	1.0	7
7	Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. Journal of Clinical Oncology, 2020, 38, 4184-4193.	0.8	74
8	First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer. Clinical Cancer Research, 2020, 26, 5178-5187.	3.2	18
9	Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptorâ€“Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance). Journal of Clinical Oncology, 2020, 38, 1284-1292.	0.8	21
10	Reply to M. Hutton-Potts and A.M. Joshua. JCO Oncology Practice, 2020, 16, 285-286.	1.4	0
11	Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. Nature Cancer, 2020, 1, 382-393.	5.7	96
12	Bridging the Gap Among Clinical Practice Guidelines for Pain Management in Cancer and Sickle Cell Disease. JCO Oncology Practice, 2020, 16, e433-e442.	1.4	1
13	Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. Journal of Clinical Oncology, 2019, 37, 2338-2348.	0.8	56
14	Real transparency in medicine: Time to act. Cancer, 2019, 125, 3924-3926.	2.0	2
15	Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up. Oncologist, 2019, 24, e646-e652.	1.9	5
16	Hydroxyapatite mineral enhances malignant potential in a tissue-engineered model of ductal carcinoma in situ (DCIS). Biomaterials, 2019, 224, 119489.	5.7	21
17	Localâ€“regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). Breast Cancer Research and Treatment, 2019, 176, 303-310.	1.1	30
18	Adjuvant Endocrine Therapy for Women With Hormone Receptorâ€“Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. Journal of Clinical Oncology, 2019, 37, 423-438.	0.8	384

#	Article	IF	Citations
19	Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer. Journal of Clinical Oncology, 2019, 37, 1868-1875.	0.8	229
20	Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer. JAMA Network Open, 2019, 2, e1916211.	2.8	7
21	Obesity-associated Breast Inflammation among Hispanic/Latina Breast Cancer Patients. Cancer Prevention Research, 2019, 12, 21-30.	0.7	9
22	CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2019, 37, 591-591.	0.8	41
23	Copper-64 trastuzumab PET imaging: a reproducibility study. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 191-198.	0.4	21
24	The Impact of Obesity on Breast Cancer. Current Oncology Reports, 2018, 20, 47.	1.8	89
25	A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease. Cancer Prevention Research, 2018, 11, 203-214.	0.7	17
26	Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier Detection. Clinical Breast Cancer, 2018, 18, 353-361.	1.1	16
27	Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer. Clinical Breast Cancer, 2018, 18, 387-394.	1.1	37
28	Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impact. Breast Cancer Research and Treatment, 2018, 167, 547-554.	1.1	18
29	Adiposity, Inflammation, and Breast Cancer Pathogenesis in Asian Women. Cancer Prevention Research, 2018, 11, 227-236.	0.7	31
30	Correlative imaging reveals physiochemical heterogeneity of microcalcifications in human breast carcinomas. Journal of Structural Biology, 2018, 202, 25-34.	1.3	41
31	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell, 2018, 34, 427-438.e6.	7.7	633
32	Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study. Breast Cancer Research and Treatment, 2018, 171, 325-334.	1.1	3
33	Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. Clinical Cancer Research, 2018, 24, 5292-5304.	3.2	73
34	Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up. BMC Cancer, 2018, 18, 42.	1.1	9
35	Longer follow-up on clinical outcomes of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2 overexpressing metastatic breast cancer.. Journal of Clinical Oncology, 2018, 36, e13005-e13005.	0.8	1
36	Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative). Journal of the American College of Surgeons, 2017, 224, 688-694.	0.2	8

#	Article	IF	Citations
37	Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score. Journal of Bone Oncology, 2017, 7, 32-37.	1.0	21
38	Reply to L.B. Marks et al. Journal of Clinical Oncology, 2017, 35, 1258-1259.	0.8	0
39	Metabolic Obesity, Adipose Inflammation and Elevated Breast Aromatase in Women with Normal Body Mass Index. Cancer Prevention Research, 2017, 10, 235-243.	0.7	114
40	Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503). Breast Cancer Research and Treatment, 2017, 163, 391-398.	1.1	16
41	The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials. European Journal of Cancer, 2017, 75, 245-258.	1.3	82
42	Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience. Oncologist, 2017, 22, 139-143.	1.9	27
43	Menopause Is a Determinant of Breast Aromatase Expression and Its Associations With BMI, Inflammation, and Systemic Markers. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1692-1701.	1.8	77
44	Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance). AAPS Journal, 2017, 19, 1411-1423.	2.2	7
45	Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. JAMA - Journal of the American Medical Association, 2017, 318, 197.	3.8	1,509
46	The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis. Breast Cancer Research and Treatment, 2017, 165, 65-76.	1.1	28
47	MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2â^' Metastatic Breast Cancer. Clinical Cancer Research, 2017, 23, 5218-5224.	3.2	492
48	RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer. Clinical Breast Cancer, 2017, 17, 585-594.e4.	1.1	39
49	Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance). Breast Cancer Research and Treatment, 2017, 164, 107-117.	1.1	68
50	Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer. Oncologist, 2017, 22, 642-647.	1.9	30
51	Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527. Journal of Clinical Oncology, 2017, 35, 421-431.	0.8	65
52	Estimating the OncotypeDX score: validation of an inexpensive estimation tool. Breast Cancer Research and Treatment, 2017, 161, 435-441.	1.1	22
53	Lymphedema, musculoskeletal events and arm function in older patients receiving adjuvant chemotherapy for breast cancer (Alliance A171302). Breast Cancer Research and Treatment, 2017, 166, 793-808.	1.1	11
54	Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design. Npj Breast Cancer, 2017, 3, 37.	2.3	84

#	Article	IF	Citations
55	Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer. Breast Cancer Research and Treatment, 2017, 166, 241-247.	1.1	16
56	21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer. Breast Cancer Research and Treatment, 2017, 166, 69-76.	1.1	31
57	Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical followâ€up. Cancer, 2017, 123, 131-137.	2.0	16
58	Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. Annals of Surgical Oncology, 2017, 24, 38-51.	0.7	80
59	Effects of Rapid Weight Loss on Systemic and Adipose Tissue Inflammation and Metabolism in Obese Postmenopausal Women. Journal of the Endocrine Society, 2017, 1, 625-637.	0.1	54
60	American Society of Clinical Oncology Summit on Addressing Obesity Through Multidisciplinary Provider Collaboration: Key Findings and Recommendations for Action. Obesity, 2017, 25, S34-S39.	1.5	12
61	A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer. Breast Cancer Research, 2017, 19, 89.	2.2	45
62	Untapped Potential of Observational Research to Inform Clinical Decision Making: American Society of Clinical Oncology Research Statement. Journal of Clinical Oncology, 2017, 35, 1845-1854.	0.8	87
63	Abstract 4705: CTLA4 blockade with HER2-directed therapy (H) yields clinical benefit in women undergoing radiation therapy (RT) for HER2-positive (HER2+) breast cancer brain metastases (BCBM). Cancer Research, 2017, 77, 4705-4705.	0.4	11
64	Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC).. Journal of Clinical Oncology, 2017, 35, 511-511.	0.8	43
65	Overall survival results of a randomized trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment.. Journal of Clinical Oncology, 2017, 35, LBA2-LBA2.	0.8	6
66	Overall survival results of a randomized trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment.. Journal of Clinical Oncology, 2017, 35, LBA2-LBA2.	0.8	21
67	Docosahexaenoic acid supplementation is not anti-inflammatory in adipose tissue of healthy obese postmenopausal women. International Journal of Nutrition, 2017, 1, 1-19.	0.8	7
68	ABC trial (A011502): A randomized phase III double blinded placebo controlled trial of aspirin as adjuvant therapy for node positive breast cancer.. Journal of Clinical Oncology, 2017, 35, TPS586-TPS586.	0.8	0
69	Phase II study of gemcitabine (G), trastuzumab (H), and pertuzumab (P) for HER2-positive metastatic breast cancer (MBC) after prior pertuzumab-based therapy.. Journal of Clinical Oncology, 2017, 35, 1037-1037.	0.8	0
70	Reply to L.A. Newman. Journal of Clinical Oncology, 2016, 34, 1015-1015.	0.8	0
71	Twentyâ€oneâ€“gene recurrence score assay in <scp>BRCA</scp>â€associated versus sporadic breast cancers: Differences based on germline mutation status. Cancer, 2016, 122, 1178-1184.	2.0	42
72	Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 324-354.	2.3	258

#	Article	IF	Citations
73	PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). Npj Breast Cancer, 2016, 2, .	2.3	80
74	Obesity and Cancer Mechanisms: Tumor Microenvironment and Inflammation. Journal of Clinical Oncology, 2016, 34, 4270-4276.	0.8	578
75	Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer. Oncologist, 2016, 21, 418-424.	1.9	46
76	26 Vlcd-Induced Rapid Weight Loss Is Accompanied by Enhanced Lipolysis, Altered Adipose Tissues With Concomitant Changes in the Fecal Microbiome and Plasma Metabolome. Gastroenterology, 2016, 150, S9.	0.6	1
77	Exocytosis of macrophage lysosomes leads to digestion of apoptotic adipocytes and foam cell formation. Journal of Lipid Research, 2016, 57, 980-992.	2.0	86
78	Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptorâ€“Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). Journal of Clinical Oncology, 2016, 34, 2602-2609.	0.8	101
79	The epichaperome is an integrated chaperome network that facilitates tumour survival. Nature, 2016, 538, 397-401.	13.7	233
80	White adipose tissue inflammation and cancerâ€specific survival in patients with squamous cell carcinoma of the oral tongue. Cancer, 2016, 122, 3794-3802.	2.0	41
81	A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling. Clinical Cancer Research, 2016, 22, 5729-5737.	3.2	175
82	Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy. Cancer Immunology Research, 2016, 4, 835-844.	1.6	138
83	Increasing Precision in Adjuvant Therapy for Breast Cancer. New England Journal of Medicine, 2016, 375, 790-791.	13.9	14
84	Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer. Clinical Breast Cancer, 2016, 16, 487-493.	1.1	13
85	Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. Practical Radiation Oncology, 2016, 6, e219-e234.	1.1	132
86	Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. Journal of Clinical Oncology, 2016, 34, 4431-4442.	0.8	182
87	Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage IIâ€“III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance). Breast Cancer Research and Treatment, 2016, 160, 297-304.	1.1	63
88	Decreased gastrointestinal toxicity associated with a novel capecitabine schedule (7 days on and 7) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	2.3	9
89	Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. New England Journal of Medicine, 2016, 375, 209-219.	13.9	507
90	Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. Journal of Clinical Oncology, 2016, 34, 2925-2934.	0.8	538

#	Article	IF	Citations
91	Hepatic Resection or Ablation for Isolated Breast Cancer Liver Metastasis. Annals of Surgery, 2016, 264, 147-154.	2.1	81
92	Response. Journal of the National Cancer Institute, 2016, 108, .	3.0	1
93	Noninvasive Detection of Inflammatory Changes in White Adipose Tissue by Label-Free Raman Spectroscopy. Analytical Chemistry, 2016, 88, 2140-2148.	3.2	22
94	Obesity and Cancerâ€"Opportunities to Break the Link. Current Breast Cancer Reports, 2016, 8, 22-31.	0.5	5
95	Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013. Journal of Clinical Oncology, 2016, 34, 2359-2365.	0.8	60
96	A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer. Clinical Breast Cancer, 2016, 16, 87-94.	1.1	1
97	Adjuvant Endocrine Therapy for Women With Hormone Receptorâ€"Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. Journal of Clinical Oncology, 2016, 34, 1689-1701.	0.8	243
98	Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. Journal of Clinical Oncology, 2016, 34, 557-565.	0.8	1,746
99	Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the Matter. Journal of Clinical Oncology, 2016, 34, 1030-1033.	0.8	82
100	The Genomic Landscape of Male Breast Cancers. Clinical Cancer Research, 2016, 22, 4045-4056.	3.2	119
101	Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer. Clinical Cancer Research, 2016, 22, 2283-2289.	3.2	154
102	Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In-situ in Patients with Lobular Neoplasia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.8	82
103	Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. JAMA Oncology, 2016, 2, 29.	3.4	68
104	Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors. Clinical Breast Cancer, 2016, 16, 276-283.	1.1	11
105	Targeting obesity-related adipose tissue dysfunction to prevent cancer development and progression. Seminars in Oncology, 2016, 43, 154-160.	0.8	27
106	Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. Journal of Clinical Oncology, 2016, 34, 542-549.	0.8	336
107	Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer. JAMA Oncology, 2016, 2, 65.	3.4	134
108	Genome Sequencing of Multiple Primary Tumors Reveals a Novel PALB2 Variant. Journal of Clinical Oncology, 2016, 34, e61-e67.	0.8	6

#	Article	IF	Citations
109	A prospective analysis of surgery and survival in stage IV breast cancer (TBCRC 013).. Journal of Clinical Oncology, 2016, 34, 1006-1006.	0.8	41
110	Pilot trial of an implantable microdevice for In Vivo drug sensitivity testing in patients with early stage, triple negative breast cancer receiving neoadjuvant therapy.. Journal of Clinical Oncology, 2016, 34, TPS1101-TPS1101.	0.8	1
111	Phase I/II trial of palbociclib in combination with bicalutamide for the treatment of androgen receptor (AR)+ metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2016, 34, TPS1103-TPS1103.	0.8	9
112	Academic and Community Cancer Research United (ACCRU) RU011301I: Adjuvant ado-trastuzumab emtansine (T-DM1) for older patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer.. Journal of Clinical Oncology, 2016, 34, TPS629-TPS629.	0.8	0
113	Accrual of older patients (pts) with breast cancer to Alliance systemic therapy trials over time: A151527.. Journal of Clinical Oncology, 2016, 34, 1024-1024.	0.8	1
114	Phase II study of gemcitabine (G), trastuzumab (H), and pertuzumab (P) for HER2-Positive metastatic breast cancer (MBC) after prior HP- or TDM/P-based therapy.. Journal of Clinical Oncology, 2016, 34, 611-611.	0.8	30
115	A genome-wide association study (GWAS) of progression-free survival (PFS) in metastatic breast cancer (MBC) patients treated with letrozole (L) with or without bevacizumab (B) in CALGB 40503.. Journal of Clinical Oncology, 2016, 34, 538-538.	0.8	0
116	Phase 1b/2 study of intratumoral Ad-RTS-hIL-12 + veledimex in patients with chemotherapy-responsive locally advanced or metastatic breast cancer.. Journal of Clinical Oncology, 2016, 34, TPS3097-TPS3097.	0.8	0
117	Abstract 4509: Clinical genomic profiling of 1000 metastatic breast cancer patients: actionable targets, novel alterations, and clinical correlations. , 2016, , .		0
118	Obesity and Cancer: Concepts and Challenges. Indian Journal of Surgical Oncology, 2015, 6, 390-398.	0.3	16
119	Big data: Are large prospective randomized trials obsolete in the future?. Breast, 2015, 24, S15-S18.	0.9	12
120	Breast Cancer, Version 1.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1475-1485.	2.3	134
121	Breast Cancer Version 2.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 448-475.	2.3	158
122	What Is the Optimum Timing of Postmastectomy Radiotherapy in Two-Stage Prosthetic Reconstruction. Plastic and Reconstructive Surgery, 2015, 135, 1509-1517.	0.7	170
123	Impact of Neoadjuvant Chemotherapy in Stage IIâ€“III Triple Negative Breast Cancer on Eligibility for Breast-conserving Surgery and Breast Conservation Rates. Annals of Surgery, 2015, 262, 434-439.	2.1	154
124	Reply to V. Amoroso et al. Journal of Clinical Oncology, 2015, 33, 291-291.	0.8	0
125	IN18 TRIPLE NEGATIVE BREAST CANCER: THE ROLE OF ANDROGEN RECEPTOR AND ITS INHIBITORS. Breast, 2015, 24, S27-S28.	0.9	0
126	Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer. New England Journal of Medicine, 2015, 372, 134-141.	13.9	598

#	Article	IF	Citations
127	Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer. Breast Cancer Research and Treatment, 2015, 149, 489-495.	1.1	72
128	Obesity and Cancer: Local and Systemic Mechanisms. Annual Review of Medicine, 2015, 66, 297-309.	5.0	217
129	The Development of Dose-Dense Adjuvant Chemotherapy. Breast Journal, 2015, 21, 42-51.	0.4	12
130	Phase II Study of Paclitaxel Given Once per Week Along With Trastuzumab and Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer. Journal of Clinical Oncology, 2015, 33, 442-447.	0.8	75
131	RTOG 9804: A Prospective Randomized Trial for Good-Risk Ductal Carcinoma In Situ Comparing Radiotherapy With Observation. Journal of Clinical Oncology, 2015, 33, 709-715.	0.8	329
132	American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. Journal of Clinical Oncology, 2015, 33, 2563-2577.	0.8	783
133	In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clinic Proceedings, 2015, 90, 996-1000.	1.4	128
134	Bilateral Mastectomy versus Breast-Conserving Surgery for Early-Stage Breast Cancer. Plastic and Reconstructive Surgery, 2015, 135, 1518-1526.	0.7	114
135	Obesity and Breast Cancer. JAMA Oncology, 2015, 1, 622.	3.4	2
136	Estrogen Protects against Obesity-Induced Mammary Gland Inflammation in Mice. Cancer Prevention Research, 2015, 8, 751-759.	0.7	28
137	Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). Journal of Clinical Oncology, 2015, 33, 2361-2369.	0.8	197
138	Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1666-1673.	3.3	79
139	Chemotherapy-related amenorrhea after adjuvant paclitaxelâ€“trastuzumab (APT trial). Breast Cancer Research and Treatment, 2015, 151, 589-596.	1.1	65
140	Menopause Is a Determinant of Breast Adipose Inflammation. Cancer Prevention Research, 2015, 8, 349-358.	0.7	90
141	Combination Trastuzumab and Chemotherapy May Have a Role in Women With Small, Node-Negative, Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer. Journal of Clinical Oncology, 2015, 33, 124-125.	0.8	2
142	Continuous Trastuzumab Therapy in Breast Cancer Patients With Asymptomatic Left Ventricular Dysfunction. Oncologist, 2015, 20, 1105-1110.	1.9	26
143	Parsing Progress in Breast Cancer. Journal of Clinical Oncology, 2015, 33, 2837-2838.	0.8	10
144	Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance). Journal of the National Cancer Institute, 2015, 107, .	3.0	52

#	Article	IF	Citations
145	Biology before Anatomy in Early Breast Cancer â€" Precisely the Point. New England Journal of Medicine, 2015, 373, 2079-2080.	13.9	35
146	Neoadjuvant Therapy in Breast Cancer as a Basis for Drug Approval. JAMA Oncology, 2015, 1, 875.	3.4	47
147	Comparison of ¹⁸F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma. Journal of Nuclear Medicine, 2015, 56, 1674-1680.	2.8	92
148	Obesity-dependent changes in interstitial ECM mechanics promote breast tumorigenesis. Science Translational Medicine, 2015, 7, 301ra130.	5.8	252
149	Recommendations for Obesity Clinical Trials in Cancer Survivors: American Society of Clinical Oncology Statement. Journal of Clinical Oncology, 2015, 33, 3961-3967.	0.8	50
150	Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance). Journal of Clinical Oncology, 2015, 33, 13-21.	0.8	782
151	Abstract CT330: Phase I study of PI3KÎ± inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC). Cancer Research, 2015, 75, CT330-CT330.	0.4	3
152	Abstract P3-04-01: Whole transcriptome analysis of AR+ ER/PR- metastatic breast cancers treated with bicalutamide on TBCRC011. , 2015, , .		1
153	Abstract P4-04-12: Both metabolic syndrome and statin use are more common in women with breast inflammation. , 2015, , .		1
154	Abstract P5-19-09: Preliminary results from a phase 2 single-arm study of enzalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). Cancer Research, 2015, 75, P5-19-09-P5-19-09.	0.4	7
155	Abstract S3-06: Mutational analysis of CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer. , 2015, , .		3
156	Abstract S4-05: Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) +/-		

#	Article	IF	Citations
163	Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2015, 33, 590-590.	0.8	20
164	Trastuzumab and pertuzumab-based versus other therapy as second-line therapy in HER2-positive metastatic breast cancer: A retrospective study from single center.. Journal of Clinical Oncology, 2015, 33, 616-616.	0.8	1
165	Adjuvant hormonal therapy in premenopausal women with breast cancer. Indian Journal of Medical and Paediatric Oncology, 2015, 36, 195-200.	0.1	4
166	Abstract P5-19-23: A phase I clinical trial of ganetespib (heat shock protein 90 inhibitor) in combination with paclitaxel and trastuzumab in human epidermal growth factor receptor-2 positive (HER2+) metastatic breast cancer. , 2015, , .		0
167	Abstract P1-09-06: A prospective longitudinal study of the impact of breast cancer treatment with adjuvant chemotherapy or tamoxifen alone on ovarian reserve. , 2015, , .		0
168	Abstract PD1-2: Impact of tumor-infiltrating B-cell clonal diversity on response to neoadjuvant therapy in triple negative and HER2+ breast cancer treated on CALGB (Alliance) 40601 and 40603. , 2015, , .		0
169	Abstract PD5-3: Phase I trial: PI3KÎ± inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC). , 2015, , .		2
170	Abstract P1-04-03: Prognostic and predictive implications of monosomy 17 in curable HER2-amplified breast cancer. , 2015, , .		0
171	Abstract P5-18-02: Trastuzumab interruption for treatment-induced cardiotoxicity in HER2 positive early breast cancer. , 2015, , .		0
172	Abstract P2-15-01: Integrated immunologic assessment of tumor infiltrating lymphocytes (TILs) and peripheral blood to assess synergy of cryoablation (cryo) plus ipilimumab (ipi) in early stage breast cancer (ESBC) patients (pts). , 2015, , .		1
173	Abstract OT3-1-05: Phase I, open-label study evaluating the safety and tolerability of LJM716, BYL719 and trastuzumab in patients with metastatic HER2+ breast cancer. , 2015, , .		0
174	Prevalence of hypomagnesemia in patients with HER2â€“positive breast cancer receiving pertuzumab treatment.. Journal of Clinical Oncology, 2015, 33, e11608-e11608.	0.8	1
175	A combined screening approach of Fracture (Fx) Risk Algorithm (FRAX) and Trabecular Bone Score (TBS) to identify osteoporotic-range fracture risk (ORFR) in breast cancer (BC) patients treated with adjuvant aromatase inhibitor (AI).. Journal of Clinical Oncology, 2015, 33, 574-574.	0.8	0
176	A model-based approach to dose optimization of neurotoxic chemotherapy for metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2015, 33, 1041-1041.	0.8	0
177	Ethnic disparities in the impact of breast cancer on the workforce: A pilot study.. Journal of Clinical Oncology, 2015, 33, e17600-e17600.	0.8	0
178	Oncotype DX in BRCA-associated vs. sporadic breast cancers: Differences based on germline mutation status and potential implications for adjuvant systemic therapy (AST).. Journal of Clinical Oncology, 2015, 33, 519-519.	0.8	0
179	Pilot study evaluating presence of crown-like structures in high grade endometrial carcinoma.. Journal of Clinical Oncology, 2015, 33, e16504-e16504.	0.8	0
180	Phase II study of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer (MBC): Updated progression-free survival with overall survival result.. Journal of Clinical Oncology, 2015, 33, 607-607.	0.8	0

#	Article	IF	Citations
181	Characterization of dominant T-cell clones by T-cell receptor (TCR) deep sequencing as a potential predictive biomarker to neoadjuvant trastuzumab (tras) in HER2-positive (HER2+) breast cancer.. Journal of Clinical Oncology, 2015, 33, 609-609.	0.8	1
182	Cardiac safety of continuous trastuzumab therapy in breast cancer patients with asymptomatic left ventricular dysfunction.. Journal of Clinical Oncology, 2015, 33, e11602-e11602.	0.8	0
183	The role of LHRH agonists in ovarian function preservation in premenopausal women undergoing chemotherapy for early stage breast cancer: A systematic review and meta-analysis.. Journal of Clinical Oncology, 2015, 33, 1050-1050.	0.8	0
184	Abstract 2876: Supplemental estrogen protects against obesity induced mammary gland inflammation in mice. , 2015, , .		0
185	Abstract 5444: Development of a noninvasive assay to determine drug concentration in tumor during hsp90 inhibitor therapy. , 2015, , .		0
186	Web based pathology assessment in RTOG 98-04. Journal of Clinical Pathology, 2014, 67, 777-780.	1.0	5
187	American Society of Clinical Oncology Position Statement on Obesity and Cancer. Journal of Clinical Oncology, 2014, 32, 3568-3574.	0.8	418
188	Building a Rapid Learning Health Care System for Oncology: The Regulatory Framework of CancerLinQ. Journal of Clinical Oncology, 2014, 32, 2373-2379.	0.8	97
189	Comorbidity, Chemotherapy Toxicity, and Outcomes Among Older Women Receiving Adjuvant Chemotherapy for Breast Cancer on a Clinical Trial: CALGB 49907 and CALGB 361004 (Alliance). Journal of Oncology Practice, 2014, 10, e285-e292.	2.5	65
190	Diminishing Relative Contraindications for Immediate Breast Reconstruction. Plastic and Reconstructive Surgery, 2014, 134, 363e-369e.	0.7	39
191	Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Hormone Receptorâ€"Positive Advanced Breast Cancerâ€"CALGB 40302 (Alliance). Journal of Clinical Oncology, 2014, 32, 3959-3966.	0.8	77
192	Frailty and Adherence to Adjuvant Hormonal Therapy in Older Women With Breast Cancer: CALGB Protocol 369901. Journal of Clinical Oncology, 2014, 32, 2318-2327.	0.8	80
193	A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer. Clinical Breast Cancer, 2014, 14, 154-160.	1.1	91
194	Maastricht Delphi Consensus on Event Definitions for Classification of Recurrence in Breast Cancer Research. Journal of the National Cancer Institute, 2014, 106, .	3.0	73
195	Impact of obesity on the survival of patients with earlyâ€stage squamous cell carcinoma of the oral tongue. Cancer, 2014, 120, 983-991.	2.0	59
196	Adjuvant Endocrine Therapy for Women With Hormone Receptorâ€"Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. Journal of Clinical Oncology, 2014, 32, 2255-2269.	0.8	661
197	Associations among survivorship care plans, experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance 369901. Journal of Cancer Survivorship, 2014, 8, 627-637.	1.5	35
198	Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance). Journal of Clinical Oncology, 2014, 32, 2311-2317.	0.8	70

#	Article	IF	Citations
199	Breast Cancer Version 3.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 542-590.	2.3	159
200	A pilot study of preoperative (Pre-op), single-dose ipilimumab (Ipi) and/or cryoablation (Cryo) in women (pts) with early-stage/resectable breast cancer (ESBC).. Journal of Clinical Oncology, 2014, 32, 1098-1098.	0.8	9
201	CK14, FOXA1, and androgen receptor (AR) expression in patients (pts) with triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2014, 32, 1126-1126.	0.8	1
202	Phase I trial of daily PI3KÎ± inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2014, 32, 2605-2605.	0.8	5
203	Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa).. Journal of Clinical Oncology, 2014, 32, 506-506.	0.8	13
204	Monitoring PIK3CA mutant allele fraction (AF) in cell-free DNA (cfDNA) in metastatic breast cancer (MBC) patients treated with PI3KÎ±â€“inhibitor plus letrozole (L) or exemestane (E).. Journal of Clinical Oncology, 2014, 32, 517-517.	0.8	1
205	Enzalutamide plus exemestane: A pilot study to assess safety, pharmacokinetics, and effects on circulating estrogens in women with advanced hormone-positive breast cancer.. Journal of Clinical Oncology, 2014, 32, 545-545.	0.8	1
206	A phase 2 single-arm study of the clinical activity and safety of enzalutamide in patients with advanced androgen receptor-positive triple-negative breast cancer.. Journal of Clinical Oncology, 2014, 32, TPS1144-TPS1144.	0.8	1
207	A multicenter phase II study of docosahexaenoic acid (DHA) in patients (pts) with a history of breast cancer (BC), premalignant lesions, or benign breast disease.. Journal of Clinical Oncology, 2014, 32, TPS1615-TPS1615.	0.8	2
208	Obesity and menopausal status as determinants of procarcinogenic breast inflammation.. Journal of Clinical Oncology, 2014, 32, 40-40.	0.8	2
209	Tumor and systemic immune responses to preoperative (pre-op) cryoablation (cryo) plus immune therapy with ipilimumab (ipi) in early-stage breast cancer (ESBC).. Journal of Clinical Oncology, 2014, 32, 64-64.	0.8	1
210	Phase II feasibility study of paclitaxel (T) with trastuzumab (H) and lapatinib (L) for node-negative, HER2-positive breast cancer (BC).. Journal of Clinical Oncology, 2014, 32, 633-633.	0.8	0
211	T-cell receptor (TCR) DNA deep sequencing to evaluate clonality of tumor-infiltrating lymphocytes (TILs) in early-stage breast cancer patients (pts) receiving preoperative cryoablation (cryo) and/or ipilimumab (ipi).. Journal of Clinical Oncology, 2014, 32, 3021-3021.	0.8	20
212	Phase 2 feasibility study of dose-dense doxorubicin and cyclophosphamide (AC) followed by eribulin mesylate with or without prophylactic growth factor (GF) for adjuvant treatment of early-stage breast cancer (EBC).. Journal of Clinical Oncology, 2014, 32, TPS670-TPS670.	0.8	0
213	A virtual consult service to optimize clinical trial participation in patients with metastatic breast cancer.. Journal of Clinical Oncology, 2014, 32, 6601-6601.	0.8	0
214	Abstract 3282: Determination of cancer susceptibility in probands with breast and ovarian cancer. , 2014, , .		0
215	A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial. Trials, 2013, 14, 228.	0.7	34
216	Omega-3 Fatty Acids for Prevention of Breast Cancer: an Update and the State of the Science. Current Breast Cancer Reports, 2013, 5, 247-254.	0.5	19

#	Article	IF	Citations
217	Genetic deletion of microsomal prostaglandin E synthase-1 suppresses mouse mammary tumor growth and angiogenesis. Prostaglandins and Other Lipid Mediators, 2013, 106, 99-105.	1.0	23
218	ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nature Genetics, 2013, 45, 1439-1445.	9.4	960
219	Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343. Journal of Clinical Oncology, 2013, 31, 2382-2387.	0.8	998
220	Phase II Trial of Bicalutamide in Patients with Androgen Receptorâ€“Positive, Estrogen Receptorâ€“Negative Metastatic Breast Cancer. Clinical Cancer Research, 2013, 19, 5505-5512.	3.2	592
221	Dietary Polyphenols Suppress Elevated Levels of Proinflammatory Mediators and Aromatase in the Mammary Gland of Obese Mice. Cancer Prevention Research, 2013, 6, 886-897.	0.7	37
222	Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907. Breast Cancer Research and Treatment, 2013, 139, 607-616.	1.1	25
223	A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer. Breast Cancer Research and Treatment, 2013, 139, 107-113.	1.1	61
224	A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors. Breast Cancer Research, 2013, 15, R110.	2.2	86
225	A planned, prospective comparison of short-term quality of life outcomes among older patients with breast cancer treated with standard chemotherapy in a randomized clinical trial vs. an observational study: CALGB #49907 and #369901. Journal of Geriatric Oncology, 2013, 4, 353-361.	0.5	11
226	Randomized Phase II Trial of Weekly vs. Every 2 Weeks vs. Every 3 Weeks Nanoparticle Albumin-Bound Paclitaxel With Bevacizumab as First-Line Chemotherapy for Metastatic Breast Cancer. Clinical Breast Cancer, 2013, 13, 239-246.e1.	1.1	27
227	Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Cancer, 2013, 119, 1776-1783.	2.0	166
228	PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. Breast Cancer Research and Treatment, 2013, 138, 457-466.	1.1	96
229	Molecular Pathways: Adipose Inflammation as a Mediator of Obesity-Associated Cancer. Clinical Cancer Research, 2013, 19, 6074-6083.	3.2	283
230	Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy. Clinical Cancer Research, 2013, 19, 491-499.	3.2	55
231	Reply to P.G. Tsoutsou et al, O. Kaidar-Person et al, and A. Courdi et al. Journal of Clinical Oncology, 2013, 31, 4571-4573.	0.8	2
232	Epoetin Alfa: To Give or Not to Give. Journal of the National Cancer Institute, 2013, 105, 1001-1003.	3.0	0
233	Pilot study of 68Ga-DOTA-F(abâ€²)2-trastuzumab in patients with breast cancer. Nuclear Medicine Communications, 2013, 34, 1157-1165.	0.5	68
234	Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2â€“Negative Advanced Breast Cancer That Progressed during or after Bevacizumab. Clinical Cancer Research, 2013, 19, 2745-2754.	3.2	62

#	Article	IF	Citations
235	ASCO's Approach to a Learning Health Care System in Oncology. Journal of Oncology Practice, 2013, 9, 145-148.	2.5	48
236	Caloric Restriction Reverses Obesity-Induced Mammary Gland Inflammation in Mice. Cancer Prevention Research, 2013, 6, 282-289.	0.7	49
237	Electrophysiological Features of Taxane-Induced Polyneuropathy in Patients With Breast Cancer. Journal of Clinical Neurophysiology, 2013, 30, 199-203.	0.9	29
238	Sequester Cuts May Delay Drug Approvalsâ€"And More. Science Translational Medicine, 2013, 5, 201ed14.	5.8	0
239	Acupuncture in the treatment of upperâ€limb lymphedema. Cancer, 2013, 119, 2455-2461.	2.0	64
240	Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer. Cancer Medicine, 2013, 2, 725-733.	1.3	54
241	Risk of metachronous breast cancer after BRCA mutationâ€"associated ovarian cancer. Cancer, 2013, 119, 1344-1348.	2.0	58
242	Longâ€term cardiac safety and outcomes of doseâ€dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer. Cancer, 2013, 119, 3943-3951.	2.0	18
243	Increased Levels of Urinary PGE-M, a Biomarker of Inflammation, Occur in Association with Obesity, Aging, and Lung Metastases in Patients with Breast Cancer. Cancer Prevention Research, 2013, 6, 428-436.	0.7	65
244	Time to Adjuvant Chemotherapy for Breast Cancer in National Comprehensive Cancer Network Institutions. Journal of the National Cancer Institute, 2013, 105, 104-112.	3.0	100
245	Feasibility of Long-Term Patient Self-Reporting of Toxicities From Home via the Internet During Routine Chemotherapy. Journal of Clinical Oncology, 2013, 31, 2580-2585.	0.8	134
246	Breast Cancer, Version 3.2013. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 753-761.	2.3	134
247	Obesity and Inflammation: New Insights into Breast Cancer Development and Progression. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, 46-51.	1.8	102
248	Obesity and Inflammation: New Insights into Breast Cancer Development and Progression. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 46-51.	1.8	89
249	Radiation therapy for breast cancer (BC) with central nervous system (CNS) metastases: A contemporary experience at Memorial Sloan-Kettering Cancer Center (MSKCC).. Journal of Clinical Oncology, 2013, 31, 144-144.	0.8	1
250	Abstract 5598: A comprehensive study to analyze tumor sensitivity to HSP90 inhibition therapy.. , 2013, , .		0
251	Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC).. Journal of Clinical Oncology, 2013, 31, 167-167.	0.8	0
252	A pilot study of preoperative (Pre-op), single-dose ipilimumab (Ipi) and/or cryoablation (Cryo) in women (pts) with early-stage/resectable breast cancer (ESBC).. Journal of Clinical Oncology, 2013, 31, 67-67.	0.8	1

#	Article	IF	Citations
253	Lessons learned from the development of the CancerLinQ prototype: Clinical decision support.. Journal of Clinical Oncology, 2013, 31, 237-237.	0.8	2
254	Phase IB Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women with Hormone Receptorâ€“Negative Breast Cancer. Cancer Prevention Research, 2012, 5, 1144-1154.	0.7	86
255	Upholding the Affordable Care Actâ€”implications for oncology. Nature Reviews Clinical Oncology, 2012, 9, 491-492.	12.5	2
256	Reply to S. Mahesh. Journal of Clinical Oncology, 2012, 30, 4446-4446.	0.8	0
257	A Genome-Wide Association Study Identifies Novel Loci for Paclitaxel-Induced Sensory Peripheral Neuropathy in CALGB 40101. Clinical Cancer Research, 2012, 18, 5099-5109.	3.2	183
258	Can We Really Use Retrospective Subset Analyses and Surveillance, Epidemiology, and End Results Data to Drive Clinical Practice?. Journal of Clinical Oncology, 2012, 30, 3148-3149.	0.8	5
259	Six Cycles of Doxorubicin and Cyclophosphamide or Paclitaxel Are Not Superior to Four Cycles As Adjuvant Chemotherapy for Breast Cancer in Women With Zero to Three Positive Axillary Nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology, 2012, 30, 4071-4076.	0.8	76
260	Choosing the Best Trastuzumab-Based Adjuvant Chemotherapy Regimen: Should We Abandon Anthracyclines?. Journal of Clinical Oncology, 2012, 30, 2179-2182.	0.8	40
261	Breast Cancer Risk Reduction: No Pain, No Gain?. Journal of Clinical Oncology, 2012, 30, 3436-3438.	0.8	12
262	Pioglitazone, a PPARÎ³ Agonist, Suppresses CYP19 Transcription: Evidence for Involvement of 15-Hydroxyprostaglandin Dehydrogenase and BRCA1. Cancer Prevention Research, 2012, 5, 1183-1194.	0.7	25
263	The role of targeted therapy and biomarkers in breast cancer treatment. Clinical and Experimental Metastasis, 2012, 29, 807-819.	1.7	36
264	Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer. Cancer, 2012, 118, 5454-5462.	2.0	55
265	A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. Lancet Oncology, The, 2012, 13, e240-e248.	5.1	64
266	Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer. Clinical Cancer Research, 2012, 18, 6784-6791.	3.2	176
267	Adoption of Gene Expression Profile Testing and Association With Use of Chemotherapy Among Women With Breast Cancer. Journal of Clinical Oncology, 2012, 30, 2218-2226.	0.8	114
268	Limited Overall Survival in Patients with Brain Metastases from Triple Negative Breast Cancer. Breast Journal, 2012, 18, 345-350.	0.4	29
269	Serum N-Telopeptide and Bone-Specific Alkaline Phosphatase Levels in Patients With Osteonecrosis of the Jaw Receiving Bisphosphonates for Bone Metastases. Journal of Oral and Maxillofacial Surgery, 2012, 70, 2768-2775.	0.5	15
270	Increased Levels of COX-2 and Prostaglandin E2 Contribute to Elevated Aromatase Expression in Inflamed Breast Tissue of Obese Women. Cancer Discovery, 2012, 2, 356-365.	7.7	228

#	Article	IF	Citations
271	A Phase I Dose-Escalation Trial of Trastuzumab and Alvespimycin Hydrochloride (KOS-1022; 17 DMAG) in the Treatment of Advanced Solid Tumors. Clinical Cancer Research, 2012, 18, 5090-5098.	3.2	58
272	Adjuvant trastuzumab reduces locoregional recurrence in women who receive breastâ€conservation therapy for lymph nodeâ€negative, human epidermal growth factor receptor 2â€positive breast cancer. Cancer, 2012, 118, 1982-1988.	2.0	80
273	Radiation field design and regional control in sentinel lymph nodeâ€positive breast cancer patients with omission of axillary dissection. Cancer, 2012, 118, 1994-2003.	2.0	25
274	Longâ€term outcomes in breast cancer patients undergoing immediate 2â€stage expander/implant reconstruction and postmastectomy radiation. Cancer, 2012, 118, 2552-2559.	2.0	113
275	Current or recent pregnancy is associated with adverse pathologic features but not impaired survival in early breast cancer. Cancer, 2012, 118, 3254-3259.	2.0	91
276	Favorable prognosis in patients with T1a/T1bN0 tripleâ€negative breast cancers treated with multimodality therapy. Cancer, 2012, 118, 4944-4952.	2.0	64
277	Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Research and Treatment, 2012, 132, 1049-1062.	1.1	286
278	A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Research and Treatment, 2012, 134, 13-20.	1.1	48
279	Return to work in lowâ€income Latina and nonâ€Latina white breast cancer survivors: A 3â€year longitudinal study. Cancer, 2012, 118, 1664-1674.	2.0	81
280	Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment, 2012, 131, 111-116.	1.1	21
281	Abstract 3908: Norton-Simon modeling for the optimization of dose and schedule of palifosfamide in breast cancer. , 2012, , .		1
282	CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2012, 30, CRA1002-CRA1002.	0.8	30
283	Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2012, 30, 134-134.	0.8	2
284	Metastatic Breast Cancer, Version 1.2012. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 821-829.	2.3	94
285	Abstract 1881: Integration of cell line and Cancer and Leukemia Group B 40101 clinical trial genome-wide association analyses implicates multiple loci in paclitaxel-induced peripheral neuropathy. , 2012, , .		0
286	Inflammation and Increased Aromatase Expression Occur in the Breast Tissue of Obese Women with Breast Cancer. Cancer Prevention Research, 2011, 4, 1021-1029.	0.7	385
287	Invasive Breast Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 136-222.	2.3	124
288	Bone Scans, Bisphosphonates, and a Lack of Acute Changes Within the Mandible. Journal of Oral and Maxillofacial Surgery, 2011, 69, 114-119.	0.5	8

#	Article	IF	Citations
289	Role of Chemotherapy in the Management of ER+ Disease. Breast, 2011, 20, S22.	0.9	0
290	Phase II Trial of Saracatinib (AZD0530), an Oral SRC-inhibitor for the Treatment of Patients with Hormone Receptor-negative Metastatic Breast Cancer. Clinical Breast Cancer, 2011, 11, 306-311.	1.1	118
291	Anthracyclines and trastuzumab; getting to the heart of the matter: when getting to the heart is the matter. Breast Cancer Research and Treatment, 2011, 127, 585-586.	1.1	0
292	Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer. Cancer, 2011, 117, 4125-4131.	2.0	16
293	Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. Cancer, 2011, 117, 5461-5468.	2.0	77
294	Obesity Is Associated with Inflammation and Elevated Aromatase Expression in the Mouse Mammary Gland. Cancer Prevention Research, 2011, 4, 329-346.	0.7	335
295	A Safety and Efficacy Pilot Study of Acupuncture for the Treatment of Chronic Lymphoedema. Acupuncture in Medicine, 2011, 29, 170-172.	0.4	38
296	p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905). Clinical Cancer Research, 2011, 17, 5170-5178.	3.2	30
297	A Feasibility Study of Bevacizumab plus Dose-Dense Doxorubicinâ€“Cyclophosphamide (AC) Followed by Nanoparticle Albuminâ€“Bound Paclitaxel in Early-Stage Breast Cancer. Clinical Cancer Research, 2011, 17, 3398-3407.	3.2	28
298	Quality of Life of Older Patients With Early-Stage Breast Cancer Receiving Adjuvant Chemotherapy: A Companion Study to Cancer and Leukemia Group B 49907. Journal of Clinical Oncology, 2011, 29, 1022-1028.	0.8	60
299	MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. Genes and Development, 2011, 25, 226-231.	2.7	193
300	Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib. Clinical Cancer Research, 2011, 17, 3490-3499.	3.2	131
301	HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab. Clinical Cancer Research, 2011, 17, 5132-5139.	3.2	396
302	Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 ⁺ breast cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 3761-3766.	3.3	291
303	Triple-Negative Breast Cancer: An Unmet Medical Need. Oncologist, 2011, 16, 1-11.	1.9	636
304	The Prostaglandin Transporter Regulates Adipogenesis and Aromatase Transcription. Cancer Prevention Research, 2011, 4, 194-206.	0.7	14
305	American Society of Clinical Oncology Endorsement of the Cancer Care Ontario Practice Guideline on Adjuvant Ovarian Ablation in the Treatment of Premenopausal Women With Early-Stage Invasive Breast Cancer. Journal of Clinical Oncology, 2011, 29, 3939-3942.	0.8	59
306	Abstract 2879: Mechanisms of integration for androgen receptor and phosphatidylinositol 3-kinase signaling in estrogen receptor negative class A breast cancer. , 2011, , .		0

#	Article	IF	Citations
307	From the Guest Editor: Triple-Negative Breast Cancer. Cancer Journal (Sudbury, Mass), 2010, 16, 10-11.	1.0	1
308	Breast Cancer: Noninvasive and Special Situations. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 1182-1207.	2.3	8
309	Dose Dense Cyclophosphamide, Methotrexate, Fluorouracil is Feasible at 14-Day Intervals: A Pilot Study of Every-14-Day Dosing as Adjuvant Therapy for Breast Cancer. Clinical Breast Cancer, 2010, 10, 440-444.	1.1	7
310	Pathologic complete response in breast cancer patients receiving anthracyclineâ€•and taxaneâ€based neoadjuvant chemotherapy. Cancer, 2010, 116, 4168-4177.	2.0	44
311	Integrated Positron Emission Tomography/Computed Tomography May Render Bone Scintigraphy Unnecessary to Investigate Suspected Metastatic Breast Cancer. Journal of Clinical Oncology, 2010, 28, 3154-3159.	0.8	121
312	Adherence and Persistence With Oral Adjuvant Chemotherapy in Older Women With Early-Stage Breast Cancer in CALGB 49907: Adherence Companion Study 60104. Journal of Clinical Oncology, 2010, 28, 2418-2422.	0.8	116
313	Cystoid Macular Edema Secondary tonab-Paclitaxel Therapy. Journal of Clinical Oncology, 2010, 28, e684-e687.	0.8	34
314	Estrogen and HER-2 Receptor Discordance Between Primary Breast Cancer and Metastasis. Oncologist, 2010, 15, 1164-1168.	1.9	159
315	Feasibility Trial of Letrozole in Combination With Bevacizumab in Patients With Metastatic Breast Cancer. Journal of Clinical Oncology, 2010, 28, 628-633.	0.8	43
316	Dose-Dense Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel With Trastuzumab and Lapatinib in HER2/neuâ€“Overexpressed/Amplified Breast Cancer Is Not Feasible Because of Excessive Diarrhea. Journal of Clinical Oncology, 2010, 28, 2982-2988.	0.8	40
317	Breast Cancer Adjuvant Chemotherapy Decisions in Older Women: The Role of Patient Preference and Interactions With Physicians. Journal of Clinical Oncology, 2010, 28, 3146-3153.	0.8	75
318	Trastuzumab-Related Cardiotoxicity Following Anthracycline-Based Adjuvant Chemotherapy: How Worried Should We Be?. Journal of Clinical Oncology, 2010, 28, 3407-3410.	0.8	49
319	American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptorâ€“Positive Breast Cancer. Journal of Clinical Oncology, 2010, 28, 3784-3796.	0.8	655
320	Neoadjuvant trial design: time for a brave new world?. Nature Reviews Clinical Oncology, 2010, 7, 359-360.	12.5	1
321	Intravenous Bisphosphonate Therapy Does Not Acutely Alter Nuclear Bone Scan Results. Clinical Breast Cancer, 2010, 10, 33-39.	1.1	8
322	Phase II Trial of Weekly Nanoparticle Albumin-Bound Paclitaxel With Carboplatin and Trastuzumab as First-line Therapy for Women With HER2-Overexpressing Metastatic Breast Cancer. Clinical Breast Cancer, 2010, 10, 281-287.	1.1	86
323	Postmastectomy intensity modulated radiation therapy following immediate expander-implant reconstruction. Radiotherapy and Oncology, 2010, 94, 319-323.	0.3	49
324	Dose-dense chemotherapy for breast cancer: what does the future hold?. Future Oncology, 2010, 6, 951-965.	1.1	8

#	Article	IF	Citations
325	Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncology, The, 2010, 11, 55-65.	5.1	1,252
326	Optimizing dose-dense regimens for early-stage breast cancer. Nature Reviews Clinical Oncology, 2010, 7, 678-679.	12.5	5
327	Adjuvant Chemotherapy for Breast Cancer: Updates and New Perspectives. Emerging Cancer Therapeutics, 2010, 1, 495-507.	0.1	0
328	Dose-Dense Adjuvant Doxorubicin and Cyclophosphamide Is Not Associated With Frequent Short-Term Changes in Left Ventricular Ejection Fraction. Journal of Clinical Oncology, 2009, 27, 6117-6123.	0.8	26
329	The 6q22.33 Locus and Breast Cancer Susceptibility. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2468-2475.	1.1	22
330	Topoisomerase IIÎ± Amplification Does Not Predict Benefit From Dose-Intense Cyclophosphamide, Doxorubicin, and Fluorouracil Therapy in HER2-Amplified Early Breast Cancer: Results of CALGB 8541/150013. Journal of Clinical Oncology, 2009, 27, 3430-3436.	0.8	45
331	Trastuzumab: A Picky Partner?. Clinical Cancer Research, 2009, 15, 6311-6313.	3.2	4
332	Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer. Clinical Cancer Research, 2009, 15, 2472-2478.	3.2	185
333	cDNA analysis demonstrates that the BRCA2 intronic variant IVS4-12del5 is a deleterious mutation. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2009, 663, 84-89.	0.4	9
334	Phase I Study of Nonpegylated Liposomal Doxorubicin plus Trastuzumab in Patients with HER2-Positive Breast Cancer. Clinical Breast Cancer, 2009, 9, 101-107.	1.1	21
335	Latent Bone Metastasis in Breast Cancer Tied to Src-Dependent Survival Signals. Cancer Cell, 2009, 16, 67-78.	7.7	609
336	A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma. Breast Cancer Research and Treatment, 2009, 115, 609-612.	1.1	13
337	The role of adjuvant anthracyclines for breast cancer treatment: Can we use molecular predictors?. Current Breast Cancer Reports, 2009, 1, 5-11.	0.5	0
338	Therapeutic options for metastatic breast cancer. Expert Opinion on Pharmacotherapy, 2009, 10, 967-981.	0.9	55
339	Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer. New England Journal of Medicine, 2009, 360, 2055-2065.	13.9	504
340	Malignant lesion segmentation in contrastâ€enhanced breast MR images based on the markerâ€controlled watershed. Medical Physics, 2009, 36, 4359-4369.	1.6	44
341	Mastectomy With Immediate Expander-Implant Reconstruction, Adjuvant Chemotherapy, and Radiation for Stage IIâ€“III Breast Cancer: Treatment Intervals and Clinical Outcomes. International Journal of Radiation Oncology Biology Physics, 2008, 70, 43-50.	0.4	51
342	Insight into Barriers Against Optimal Adherence to Oral Hormonal Therapy in Women with Breast Cancer. Clinical Breast Cancer, 2008, 8, 155-161.	1.1	73

#	Article	IF	Citations
343	Prolonged Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel in Breast Cancer Is Feasible. Clinical Breast Cancer, 2008, 8, 418-424.	1.1	12
344	Dose-escalation of filgrastim does not improve efficacy: Clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. Cancer Treatment Reviews, 2008, 34, 223-230.	3.4	14
345	Cyclooxygenase-2-derived Prostaglandin E2 Stimulates Id-1 Transcription. Journal of Biological Chemistry, 2008, 283, 33955-33968.	1.6	27
346	Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study. Journal of Clinical Oncology, 2008, 26, 1331-1337.	0.8	522
347	EP2 and EP4 Receptors Regulate Aromatase Expression in Human Adipocytes and Breast Cancer Cells. Journal of Biological Chemistry, 2008, 283, 3433-3444.	1.6	86
348	Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840. Journal of Clinical Oncology, 2008, 26, 1642-1649.	0.8	548
349	Dose-Dense Chemotherapy With Trastuzumab Is an Appropriate Option. Journal of Clinical Oncology, 2008, 26, 3655-3656.	0.8	2
350	Racial Differences in Clinical Outcomes From Metastatic Breast Cancer: A Pooled Analysis of CALGB 9342 and 9840â€"Cancer and Leukemia Group B. Journal of Clinical Oncology, 2008, 26, 2659-2665.	0.8	31
351	Phase I Study of a Novel Capecitabine Schedule Based on the Norton-Simon Mathematical Model in Patients With Metastatic Breast Cancer. Journal of Clinical Oncology, 2008, 26, 1797-1802.	0.8	60
352	The Safety of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Trastuzumab in HER-2/neu Overexpressed/Amplified Breast Cancer. Journal of Clinical Oncology, 2008, 26, 1216-1222.	0.8	56
353	Genetically Guided Choices for Chemotherapyâ€"Reply. JAMA - Journal of the American Medical Association, 2008, 299, 1543.	3.8	0
354	Occult Axillary Node Metastases in Breast Cancer Are Prognostically Significant: Results in 368 Node-Negative Patients With 20-Year Follow-Up. Journal of Clinical Oncology, 2008, 26, 1803-1809.	0.8	140
355	A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer. Clinical Cancer Research, 2008, 14, 7878-7883.	3.2	109
356	Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial. Journal of Clinical Oncology, 2008, 26, 1231-1238.	0.8	485
357	The Taxane Limbo: How Low Can We Go?. Journal of the National Cancer Institute, 2008, 100, 761-763.	3.0	4
358	Immunization of High-Risk Breast Cancer Patients with Clustered sTn-KLH Conjugate plus the Immunologic Adjuvant QS-21. Clinical Cancer Research, 2007, 13, 2977-2985.	3.2	83
359	Randomized, Controlled Trial of Acupuncture for the Treatment of Hot Flashes in Breast Cancer Patients. Journal of Clinical Oncology, 2007, 25, 5584-5590.	0.8	171
360	Toxicity of Older and Younger Patients Treated With Adjuvant Chemotherapy for Node-Positive Breast Cancer: The Cancer and Leukemia Group B Experience. Journal of Clinical Oncology, 2007, 25, 3699-3704.	0.8	282

#	Article	IF	Citations
361	HER2 and Response to Paclitaxel in Node-Positive Breast Cancer. New England Journal of Medicine, 2007, 357, 1496-1506.	13.9	531
362	Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System. Journal of Clinical Oncology, 2007, 25, 2127-2132.	0.8	709
363	Combination of Trastuzumab and Tanespimycin (17-AAG, KOS-953) Is Safe and Active in Trastuzumab-Refractory HER-2â€“Overexpressing Breast Cancer: A Phase I Dose-Escalation Study. Journal of Clinical Oncology, 2007, 25, 5410-5417.	0.8	333
364	BRCA Mutations in Women with Ductal Carcinoma In situ. Clinical Cancer Research, 2007, 13, 4306-4310.	3.2	29
365	Preoperative Chemotherapy for Breast Cancer. JAMA - Journal of the American Medical Association, 2007, 298, 2665.	3.8	13
366	Intensive Dose-Dense Compared With High-Dose Adjuvant Chemotherapy for High-Risk Operable Breast Cancer: Southwest Oncology Group/Intergroup Study 9623. Journal of Clinical Oncology, 2007, 25, 1677-1682.	0.8	45
367	Increased Dose Density Is Feasible: A Pilot Study of Adjuvant Epirubicin and Cyclophosphamide followed by Paclitaxel, at 10- or 11-Day Intervals with Filgrastim Support in Women with Breast Cancer. Clinical Cancer Research, 2007, 13, 223-227.	3.2	11
368	Breast Cancer Chemotherapy. Cancer Journal (Sudbury, Mass), 2007, 13, 141-147.	1.0	15
369	Adjuvant Chemotherapy for Early-Stage Breast Cancer. Hematology/Oncology Clinics of North America, 2007, 21, 207-222.	0.9	2
370	Trastuzumab â€" Mechanism of Action and Use in Clinical Practice. New England Journal of Medicine, 2007, 357, 39-51.	13.9	2,140
371	Adjuvant treatment recommendations in older women with breast cancerâ€"A survey of oncologists. Critical Reviews in Oncology/Hematology, 2007, 61, 255-260.	2.0	32
372	Ixabepilone. Nature Reviews Drug Discovery, 2007, 6, 953-954.	21.5	56
373	Dose-Dense Therapy in the Treatment of Early-Stage Breast Cancer: An Overview of the Data. Clinical Breast Cancer, 2007, 8, S6-S10.	1.1	12
374	Current status of the taxanes as adjuvant therapy for breast cancer. Breast, 2007, 16, 132-135.	0.9	1
375	A Case Series of Androgen Use in Breast Cancer Survivors with Sexual Dysfunction. Journal of Sexual Medicine, 2007, 4, 1769-1774.	0.3	17
376	CALGB 9344/CALGB C9741: What have we learned?. European Journal of Cancer, Supplement, 2006, 4, 10-12.	2.2	1
377	Inadvertent Use of Aromatase Inhibitors in Patients with Breast Cancer with Residual Ovarian Function: Cases and Lessons. Clinical Breast Cancer, 2006, 7, 158-161.	1.1	25
378	A Phase I Study of Cetuximab/Paclitaxel in Patients with Advanced-Stage Breast Cancer. Clinical Breast Cancer, 2006, 7, 270-277.	1.1	86

#	Article	IF	Citations
379	Cognitive Function of Older Patients Receiving Adjuvant Chemotherapy for Breast Cancer: A Pilot Prospective Longitudinal Study. Journal of the American Geriatrics Society, 2006, 54, 925-931.	1.3	242
380	A Prospective, Longitudinal Study of the Functional Status and Quality of Life of Older Patients with Breast Cancer Receiving Adjuvant Chemotherapy. Journal of the American Geriatrics Society, 2006, 54, 1119-1124.	1.3	86
381	Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patientâ€™s perspective. Breast Cancer Research and Treatment, 2006, 98, 343-348.	1.1	85
382	Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806. Breast Cancer Research and Treatment, 2006, 100, 301-308.	1.1	26
383	Pharmacokinetics and Toxicity of Weekly Docetaxel in Older Patients. Clinical Cancer Research, 2006, 12, 6100-6105.	3.2	72
384	Trastuzumab adds to adjuvant chemotherapy for resected HER2-positive breast cancer. Nature Clinical Practice Oncology, 2006, 3, 12-13.	4.3	4
385	Can Granulocyte-Colony Stimulating Factor Worsen Anemia?. Journal of Clinical Oncology, 2006, 24, 2985-2986.	0.8	2
386	Cancer and Leukemia Group B Breast Committee: Decades of Progress and Plans for the Future: Fig. 1.. Clinical Cancer Research, 2006, 12, 3576s-3580s.	3.2	2
387	Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer. JAMA - Journal of the American Medical Association, 2006, 295, 1658.	3.8	645
388	HER-2/neu Status Is a Determinant of Mammary Aromatase Activity In vivo: Evidence for a Cyclooxygenase-2-Dependent Mechanism. Cancer Research, 2006, 66, 5504-5511.	0.4	86
389	Dietary Fat Reduction and Breast Cancer Outcome: Interim Efficacy Results From the Women's Intervention Nutrition Study. Journal of the National Cancer Institute, 2006, 98, 1767-1776.	3.0	745
390	Radiation Pneumonitis in Breast Cancer Patients Treated with Taxanes: Does Sequential Radiation Therapy Lower the Risk?. Breast Journal, 2005, 11, 317-320.	0.4	11
391	The best use of adjuvant chemotherapy: New drugs and new use of â€œoldâ€•drugs. Breast, 2005, 14, 570-575.	0.9	4
392	Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations inBRCA1 orBRCA2. Cancer, 2005, 103, 44-51.	2.0	132
393	The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975-1999. Cancer, 2005, 104, 1149-1157.	2.0	116
394	Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer, 2005, 104, 1575-1579.	2.0	167
395	Developing a cancer-specific geriatric assessment. Cancer, 2005, 104, 1998-2005.	2.0	541
396	A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast Cancer Research and Treatment, 2005, 90, 157-163.	1.1	84

#	Article	IF	Citations
397	Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy. Breast Cancer Research and Treatment, 2005, 92, 151-156.	1.1	47
398	HER2/neu-Induced Mammary Tumorigenesis and Angiogenesis Are Reduced in Cyclooxygenase-2 Knockout Mice. Cancer Research, 2005, 65, 10113-10119.	0.4	145
399	Testing Chemotherapy for Breast Cancer: Timing Is Everything. Journal of Clinical Oncology, 2005, 23, 5434-5436.	0.8	10
400	Adjuvant Chemotherapy in Older and Younger Women With Lymph Nodeâ€“Positive Breast Cancer. JAMA - Journal of the American Medical Association, 2005, 293, 1073.	3.8	371
401	Phosphorylated/Activated HER2 as a Marker of Clinical Resistance to Single Agent Taxane Chemotherapy for Metastatic Breast Cancer. Cancer Investigation, 2005, 23, 483-487.	0.6	37
402	American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptorâ€“Positive Breast Cancer: Status Report 2004. Journal of Clinical Oncology, 2005, 23, 619-629.	0.8	810
403	Weekly Epoetin Alfa During Adjuvant Chemotherapy for Breast Cancer: Effect on Hemoglobin Levels and Quality of Life. Clinical Breast Cancer, 2005, 6, 132-142.	1.1	25
404	Effect of Creatinine Clearance on Patterns of Toxicity in Older Patients Receiving Adjuvant Chemotherapy for Breast Cancer. Drugs and Aging, 2005, 22, 785-791.	1.3	25
405	Clinical implications of antiangiogenic therapies. Oncology, 2005, 19, 26-31.	0.4	14
406	Introduction: Examining the Potential Impact of Anemia Treatment on Clinical Outcomes in Anemic Cancer Patients. Oncologist, 2004, 9, 1-3.	1.9	1
407	Phase II Study of Feasibility of Dose-Dense FEC Followed by Alternating Weekly Taxanes in High-Risk, Four or More Node-Positive Breast Cancer. Clinical Cancer Research, 2004, 10, 5754-5761.	3.2	31
408	Phase II Study of Celecoxib and Trastuzumab in Metastatic Breast Cancer Patients Who Have Progressed after Prior Trastuzumab-Based Treatments. Clinical Cancer Research, 2004, 10, 4062-4067.	3.2	61
409	Epoetin Alfa: Future Directions and Future Research. Oncologist, 2004, 9, 70-73.	1.9	1
410	Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer. New England Journal of Medicine, 2004, 351, 971-977.	13.9	958
411	Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342. Journal of Clinical Oncology, 2004, 22, 2061-2068.	0.8	257
412	HER-2 Testing in Breast Cancer Using Immunohistochemical Analysis and Fluorescence In Situ Hybridization. American Journal of Clinical Pathology, 2004, 121, 631-636.	0.4	144
413	rHuEPO and Treatment Outcomes: the Clinical Experience. Oncologist, 2004, 9, 55-69.	1.9	20
414	Dose-dense chemotherapy in breast cancer and lymphoma. Seminars in Oncology, 2004, 31, 19-26.	0.8	30

#	Article	IF	Citations
415	Cardiac profiles of liposomal anthracyclines. Cancer, 2004, 100, 2052-2063.	2.0	117
416	Cytokeratin-positive cells in sentinel lymph nodes in breast cancer are not random events. Cancer, 2004, 101, 926-933.	2.0	52
417	A tool for predicting breast carcinoma mortality in women who do not receive adjuvant therapy. Cancer, 2004, 101, 2509-2515.	2.0	42
418	Expedition Inspiration Fund for Breast Cancer Research Meeting 2003. Breast Cancer Research and Treatment, 2003, 80, 139-144.	1.1	0
419	Epithelial lesions in prophylactic mastectomy specimens from women withBRCA mutations. Cancer, 2003, 97, 1601-1608.	2.0	90
420	Factors influencing treatment patterns of breast cancer patients age 75 and older. Critical Reviews in Oncology/Hematology, 2003, 46, 121-126.	2.0	119
421	Follow-up care of breast cancer survivors. Critical Reviews in Oncology/Hematology, 2003, 48, 89-99.	2.0	16
422	Current Status and Future Directions in Breast Cancer Therapy. Clinical Breast Cancer, 2003, 4, S70-S75.	1.1	27
423	The use of taxanes in early breast cancer. European Journal of Cancer, Supplement, 2003, 1, 1-10.	2.2	5
424	A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Research, 2003, 6, R8-R17.	2.2	262
425	American Society of Clinical Oncology Technology Assessment Working Group Update: Use of Aromatase Inhibitors in the Adjuvant Setting. Journal of Clinical Oncology, 2003, 21, 2597-2599.	0.8	81
426	Assessment of Molecular Markers of Clinical Sensitivity to Single-Agent Taxane Therapy for Metastatic Breast Cancer. Journal of Clinical Oncology, 2002, 20, 2319-2326.	0.8	76
427	American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Women With Hormone Receptorâ€“Positive Breast Cancer: Status Report 2002. Journal of Clinical Oncology, 2002, 20, 3317-3327.	0.8	213
428	Prospective Exploratory Analysis of the Association Between Tumor Response, Quality of Life, and Expenditures Among Patients Receiving Paclitaxel Monotherapy for Refractory Metastatic Breast Cancer. Journal of Clinical Oncology, 2002, 20, 3665-3673.	0.8	28
429	Risk-Reducing Salpingo-oophorectomy in Women with aBRCA1orBRCA2Mutation. New England Journal of Medicine, 2002, 346, 1609-1615.	13.9	1,363
430	Single-agent vs combination therapy in advanced breast cancer: potential roles of capecitabine. Oncology, 2002, 16, 13-6.	0.4	19
431	Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification. Journal of Clinical Oncology, 2001, 19, 2587-2595.	0.8	531
432	Postmastectomy Radiotherapy: Clinical Practice Guidelines of the American Society of Clinical Oncology*. Journal of Clinical Oncology, 2001, 19, 1539-1569.	0.8	742

#	Article	IF	Citations
433	Oral Gossypol in the Treatment of Patients with Refractory Metastatic Breast Cancer: A Phase I/II Clinical Trial. Breast Cancer Research and Treatment, 2001, 66, 239-248.	1.1	189
434	A pilot study of Interpersonal Psychotherapy by telephone with cancer patients and their partners. , 2000, 9, 44-56.		102
435	An immunotherapeutic approach to treatment of breast cancer: focus on trastuzumab plus paclitaxel. Cancer Chemotherapy and Pharmacology, 2000, 46, S23-S26.	1.1	6
436	Role of Taxanes in Adjuvant Therapy. Cancer Investigation, 2000, 18, 32-38.	0.6	5
437	A pilot study of Interpersonal Psychotherapy by telephone with cancer patients and their partners. , 2000, 9, 44.		8
438	Breast Conservation Therapy for Invasive Breast Cancer in Ashkenazi Women With BRCA Gene Founder Mutations. Journal of the National Cancer Institute, 1999, 91, 2112-2117.	3.0	167
439	ADJUVANT THERAPY FOR RESECTABLE BREAST CANCER. Hematology/Oncology Clinics of North America, 1999, 13, 391-413.	0.9	6
440	Lack of Increased Cardiac Toxicity with Sequential Doxorubicin and Paclitaxel. Cancer Investigation, 1998, 16, 67-71.	0.6	9
441	Paclitaxel-Induced Pancreatitis: A Case Report. Journal of the National Cancer Institute, 1997, 89, 91-93.	3.0	16
442	Is There an Alternative to Alternating Adjuvant Therapy for Breast Cancer?. Cancer Investigation, 1994, 12, 329-335.	0.6	2
443	Do We Need a â€œStopping Ruleâ€•for Breast Cancer?. Cancer Investigation, 1994, 12, 543-544.	0.6	0
444	Phase II trial of carboplatin and etoposide in metastatic breast cancer. Cancer, 1993, 71, 1254-1257.	2.0	15
445	Taxol and Recombinant Human Granulocyte Colony-Stimulating Factor, an Active Regimen as Initial Therapy for Metastatic Breast Cancer.. Annals of the New York Academy of Sciences, 1993, 698, 398-402.	1.8	1
446	A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer, 1991, 68, 965-969.	2.0	79